Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II [Session Title: Poster Session III]

Conclusions: Patients with new-onset AF are frequently treated with novel anticoagulants and these patients have lower risk scores than those with known AF transitioned to a novel drug. These data will provide insights into clinical management and patient centered outcomes among those treated with novel anticoagulants in real world practice settings.

Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Steinberg, B. A., Milford-Beland, S., Ollis, D., Blanco, R., Ansell, J., Fonarow, G. C., Gersh, B., Go, A., Hylek, E., Kowey, P. R., Mahaffey, K. W., Thomas, L., Chang, P., Peterson, E. D., Piccini, J. P. Tags: Session Title: Poster Session III Source Type: research